<DOC>
	<DOCNO>NCT00390611</DOCNO>
	<brief_summary>This trial compare efficacy toxicity standard first-line chemotherapy alone vs. standard chemotherapy plus sorafenib patient stage III/IV ovarian cancer follow cytoreductive surgery . Patients residual large volume disease and/or bowel involvement exclude , minimize risk bowel perforation .</brief_summary>
	<brief_title>Paclitaxel Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer</brief_title>
	<detailed_description>All patient must least 4 week cytoreductive surgery start treatment . Patients randomize receive treatment either paclitaxel/carboplatin + sorafenib paclitaxel/carboplatin . Paclitaxel/carboplatin repeat every 21 day maximum 6 cycle . Patients objective response/stable disease complete 6 course chemotherapy continue sorafenib disease progression total 12 month . - Regimen A : Paclitaxel 175 mg/m2 1-3 hour IV infusion , Day 1 Carboplatin AUC 6 infuse 20 minute IV , Day 1 Sorafenib 400mg PO bid - Regimen B : Paclitaxel 175mg/m2 , 1-3 hour IV infusion , Day 1 Carboplatin AUC 6.0 , 20 minute IV infusion , Day 1</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Histologically confirm , stage III IV epithelial ovarian carcinoma 2 . No previous treatment chemotherapy radiation therapy 3 . All patient must undergo cytoreductive surgery , follow result : 1 . No residual tumor nodule &gt; 3cm 2 . No residual tumor involvement bowel ( ie . invasion bowel wall ) 3 . No residual intestinal obstruction 4 . Measurable evaluable disease . Patients elevate CA125 level and/or evaluable disease per RECIST criterion eligible . 5 . ECOG performance status 0 1 . 6 . ANC ≥ 1500/µL , platelet ≥ 100,000/µL , hemoglobin ≥ 9.0 g/dL . 7 . Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) , ALT AST ≤ 2.5 x ULN ( ≤ 5 x ULN patient liver metastasis ) 8 . Serum creatinine _ 1.5 x ULN 9 . INR &lt; 1.5 PT/PTT within normal limit . Patients receive anticoagulation treatment agent warfarin heparin may allow participate . For patient warfarin , INR may &gt; 1.5 , measure prior initiation sorafenib monitor least weekly INR stable desire therapeutic range . 10 . Women childbearing potential must negative serum pregnancy test perform within 7 day prior start treatment . 11 . Patients must able understand nature study give write informed consent . 1 . Age &lt; 18 year 2 . Active cardiac disease , include : A ) congestive heart failure &gt; class II NYHA , B ) unstable angina onset angina within last 3 month , C ) myocardial infarction within 6 month 3 . Cardiac ventricular arrhythmia require antiarrhythmic therapy 4 . Patients CNS metastasis . Patients neurological symptom must undergo CT scan/MRI brain exclude brain metastasis . 5 . Uncontrolled hypertension define systolic blood pressure &gt; 150mmHg diastolic pressure &gt; 90mmHg , despite optimal medical management 6 . Known HIV , chronic hepatitis B chronic hepatitis C infection 7 . Women pregnant lactating . Women childbearing potential must agree use adequate contraception time study entry least 3 month last administration study drug . 8 . Active clinically serious infection ( &gt; grade 2 ) 9 . Thrombotic embolic event cerebral vascular accident include transient ischemic attack within last 6 month . 10 . Pulmonary hemorrhage/bleeding event ≥ grade 2 within 4 week start treatment . 11 . Any hemorrhage/bleeding event ≥ grade 3 within 4 week start treatment 12 . Serious nonhealing wound , ulcer , bone fracture 13 . Evidence history bleed diathesis coagulopathy 14 . Major surgery , open biopsy , significant traumatic injury within 4 week start treatment . 15 . Any condition impairs ability swallow whole pill 16 . Patients type malabsorption 17 . Known suspected allergy agent use treatment 18 . Use St. John 's Wort rifampin</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Ovarian Cancer</keyword>
</DOC>